PitchSend

Investor Presentaiton

III Key Investment Highlights 6 Robust Financial Performance Robust financial performance with double digit top line and bottom line growth Gross Revenue¹ | EGP mn Gross Profit | EGP mn, % EBITDA & Margin | EGP mn, % CAGR 31% 7,372 5,439 4,302 3,361 CAGR 37% 8.6% 9,818 7.9% 7.2% 7.3% 6.8% 826 569 394 307 228 CAGR 46% 4.2% 406 3.2% 2.9% 2.9% 2.7% 229 155 122 89 IN 2013 2014 2015 2016 2017 2013 2014 2015 2016 2017 2013 2014 2015 2016 2017 Net Profit & Margin | EGP mn, % CAGR 50% ROE | % 1.8% 41% 36% 1.4% 32% 33% 170 1.1% 1.0% 0.9% 102 57 35 38 2013 2014 2015 2016 2017 47% 2013 2014 2015 2016 2017 Return on Fixed Assets | % 48% 42% 37% 63% 89% 2013 2014 2015 2016 2017 ibnsinapharma Source: Company Management (1): Pro forma gross revenue includes part of 3PL revenue that was stated as other income until 2016 18

View entire presentation